Literature DB >> 20126990

Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma.

Lenka Stefancikova1, Mojmir Moulis, Pavel Fabian, Barbora Ravcukova, Ingrid Vasova, Jan Muzik, Jitka Malcikova, Iva Falkova, Jana Slovackova, Jana Smardova.   

Abstract

Mantle cell lymphoma (MCL) is typified by translocation t(11;14)(q13;q32) causing upregulation of cyclin D1 and deregulation of cell cycle. The cyclin D1 activation plays a critical role in MCL pathogenesis but additional oncogenic events, such as aberrations of the ARF/MDM2/p53 pathway are also necessary for progression of the disease. We analyzed the p53 tumor suppressor in tumor tissue of 33 patients with MCL. The p53 status was determined by functional analyses in yeast (FASAY) and by cDNA sequencing. The level of the p53 protein was assessed by immunohistochemistry and immunoblotting. Loss of the p53-specific locus 17p13.3 was detected by FISH. Mutations in the p53 gene were detected in nine samples and they included eight missense mutations and one short deletion causing frame shift and premature stop codon formation in position 169. This mutation was associated with mRNA decay as revealed by sequencing of the p53 gDNA. All eight missense mutations were manifested by accumulation of the p53 protein in nuclei of tumor cells and three of them exhibited loss of the p53-specific locus 17p13.3. The p53 mutations were shown to be a negative prognostic marker in MCL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20126990     DOI: 10.3892/ijo_00000545

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  15 in total

1.  Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.

Authors:  Peter L Roberson; Lauren B Smith; Meredith A Morgan; Matthew J Schipper; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2017-10-30       Impact factor: 3.099

2.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2010-06-02       Impact factor: 0.196

3.  TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.

Authors:  Hua-Jie Dong; Li-Tao Zhou; Cheng Fang; Lei Fan; Dan-Xia Zhu; Yin-Hua Wang; Jian-Yong Li; Wei Xu
Journal:  Med Oncol       Date:  2011-11-06       Impact factor: 3.064

4.  Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.

Authors:  Mathieu Gallo; Valère Cacheux; Laure Vincent; Caroline Bret; Ariane Tempier; Caroline Guittard; Alexandra Macé; Nicolas Leventoux; Valérie Costes; Vanessa Szablewski
Journal:  Virchows Arch       Date:  2016-09-07       Impact factor: 4.064

5.  Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.

Authors:  Elena N Voropaeva; Tatyana I Pospelova; Mikhail I Voevoda; Vladimir N Maksimov; Yuriy L Orlov; Olga B Seregina
Journal:  BMC Med Genomics       Date:  2019-03-13       Impact factor: 3.063

Review 6.  High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.

Authors:  Edward Nabrinsky; Alexey V Danilov; Paul B Koller
Journal:  Curr Hematol Malig Rep       Date:  2021-01-28       Impact factor: 3.952

Review 7.  TP53 status and response to treatment in breast cancers.

Authors:  Mariana Varna; Guilhem Bousquet; Louis-François Plassa; Philippe Bertheau; Anne Janin
Journal:  J Biomed Biotechnol       Date:  2011-05-09

8.  The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.

Authors:  Meaghan Wall; Gretchen Poortinga; Kym L Stanley; Ralph K Lindemann; Michael Bots; Christopher J Chan; Megan J Bywater; Kathryn M Kinross; Megan V Astle; Kelly Waldeck; Katherine M Hannan; Jake Shortt; Mark J Smyth; Scott W Lowe; Ross D Hannan; Richard B Pearson; Ricky W Johnstone; Grant A McArthur
Journal:  Cancer Discov       Date:  2012-12-14       Impact factor: 39.397

9.  Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.

Authors:  Caixia Jing; Yuhuan Zheng; Yu Feng; Xia Cao; Caigang Xu
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

Review 10.  Progress in molecular feature of smoldering mantle cell lymphoma.

Authors:  Panruo Jiang; Aakash Desai; Haige Ye
Journal:  Exp Hematol Oncol       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.